TSO3, a sterilisation technology company for medical devices in healthcare settings, has provided an update on its 2016 operating activities
During 2016, TSO3 shipped a total of 110 Sterizone VP4 Sterilisers to Getinge Infection Control, its exclusive global distribution partner, with 30 of those units being shipped in the fourth quarter of 2016.
The company also supported Getinge in the installation of Sterizone VP4 Sterilisers into multiple medical facilities in Canada and the US.
The Steriliser is a low-temperature sterilisation system that utilises the dual-sterilants of vaporised hydrogen peroxide (H2O2) and ozone (O3) to achieve terminal sterilisation of heat and moisture sensitive medical devices.
In 2016, the company expanded its commercialisation and laboratory capacity in response to experienced and anticipated growth. The company's European commercial launch is planned for the first quarter of 2017.
TSO3 also signed with a number of leading healthcare institutions in 2016 under its recently announced Strategic Partnership Programme.
This is a programme where healthcare institutions work with TSO3 to study the impact of the company's industry changing technology on traditional sterilisation practices and the processes to enable the routine terminal sterilisation of multi-channel flexible endoscopes.
The company also made significant advances during the year toward further expanding its labelling claims to include multi-channeled flexible endoscopes containing guide wire mechanisms, such as duodenoscopes.
TSO3 continues to target a related filing with the US Food and FDA in the first quarter of 2017.
Finally, TSO3 completed the construction of its new Compatibility Testing Service (CTS) laboratory in Myrtle Beach, South Carolina.
During its Analyst Day in Myrtle Beach, the company provided Original Equipment Manufacturers with information to support the use of TSO3's technology with their instrumentation.
Ric Rumble, Chief Executive Officer of TSO3, said: "We thank Getinge's global and North American management team, along with its low temperature sterilisation specialist, for participating in our event.”
He added that the contributions from these individuals “clearly articulate the buzz that our technology is creating in the industry, how it is sold and used in hospitals, and its potential impact on reprocessing of multi-channel flexible endoscopes."